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The EPM2A gene, encoding the dual-phosphatase laforin, is mutated in a fatal form of progressive myoclonus
epilepsy known as Lafora disease (LD). The EPM2A gene, by differential splicing of its transcripts, is known
to encode two laforin isoforms having distinct carboxyl termini; a major isoform localized in the cytoplasm
(laf331), and a minor isoform that is targeted to the nucleus as well (laf317). We show here that the two laforin
isoforms interact with each other and form homo and heterodimers. The homodimer of laf331 display robust
phosphatase activity, whereas the laf317 homodimer and the laf331–laf317 heterodimer lack phosphatase
activity. Laf331 binds to glycogen only as a monomeric form. Laf317, on the other hand, was unable to
bind to glycogen as a homodimer or as a heterodimer. Similar to laf331, laf317 interacts with and functions
as a substrate for the malin ubiquitin ligase—a product of another gene defective in LD. Malin, however,
shows higher affinity towards laf331 when compared with laf317. We have also tested the effect of LD-
associated mutations, whose effects are restricted to the laf331 isoform, on laf331–laf317 interaction. Two
such mutations are known and both abolish the interactions between laf317 and laf331 and their heterodimer-
ization, but not the homodimerization property of laf331. Thus, laf317 could function as a dominant-negative
regulator of laf331, and laf331-specific mutations might affect laf317 functions as well. Thus, our findings
reveal a novel mechanism for the EPM2A gene function, regulated by alternative splicing, in normal as
well as disease conditions.
INTRODUCTION
The Lafora-type progressive myoclonus epilepsy, also known
as Lafora disease (LD), is an autosomal form of genetic dis-
order characterized by the presence of Lafora polyglucosan
bodies in the affected tissues, including the neurons (1). The
symptoms of LD include myoclonic and absence seizures,
drop attacks, ataxia and a quickly developing, progressive
and severe dementia (2). LD is caused by at least three
genes, of which two have been identified and characterized.
These are EPM2A and NHLRC1 (reviewed in 1). The
NHLRC1 gene encodes an E3 ubiquitin ligase and LD-
associated mutations affect its ligase activity and/or the
subcellular localization (3–5). The EPM2A gene product
laforin is a dual-specificity protein phosphatase (6,7) and
LD-associated mutations are known to affect its phosphatase
activity, glycogen binding affinity and subcellular localization
(7–12). Laforin and malin physically interact, co-localize and
thought to work together in cellular cascades that are critical
for neuronal functions (1,3–5). Consistent with this view,
malin was shown to ubiquitinate protein targeting to glycogen
(PTG), a regulatory subunit of protein phosphatase-1, which
enhances glycogen accumulation in a laforin-dependent manner
(13,14). Thus, loss of functional laforin or malin would
result in increased PTG levels, leading to the genesis of poly-
glucosan inclusions in the neurons (13–15).
The EPM2A transcript in human is known to undergo
alternative splicing resulting in the production of at least
two laforin isoforms with distinct carboxyl termini, one
localizing in the cytoplasm and the other in the nucleus (16).
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Intriguingly, two mutations in the EPM2A gene that specifi-
cally target the cytoplasmic isoform are known in LD
(17,18). It has been suggested, therefore, that the nuclear
isoform is not relevant to the LD pathology (17). Since the
cytoplasmic laforin is known to form homodimers and the
dimerization is required for the enzymatic activity (12), we
have recently proposed that the two isoforms of laforin
could form heterodimers with distinct functional properties
(18). In this report, we demonstrate the physical interaction
between laforin isoforms and with malin, and show that the
nuclear isoform exhibits a dominant-negative activity over
the cytoplasmic form.
RESULTS
Laforin isoforms physically interact with each other
and form homo- and heterodimers
Differential splicing in the EPM2A gene transcript lead to the
production of two distinct laforin isoforms with distinct
carboxyl-termini: a 331 amino acid long major cytoplasmic
isoform (hereafter identified as laf331) (7), and a 317
residue long minor nuclear isoform of laforin (laf317) (16)
(see Fig. 1A and B). Because laf331 is known to form func-
tional dimers (12), we wanted to check whether laf317
would also form dimer with itself (homodimer) and/or with
the laf331 (heterodimer). For this, we created laf331 and
laf317 expression constructs having the amino-terminal
FLAG tag or the carboxyl-terminal Myc/His tag (see Materials
and Methods). Transient expression of these constructs
showed distinct localization patterns for the two isoforms as
demonstrated earlier (16); laf331 was predominantly cyto-
plasmic in localization, whereas laf317 was localized both in
nucleus and cytoplasm (Fig. 1C). We next established that
both laf317 and laf331 form dimers in vivo. For this, we tran-
siently expressed laf317 and laf331 in COS-7 cells, either
treated or not treated with a chemical cross-linker, disuccini-
midyl suberate (DSS), and then analyzed by immunoblotting.
As shown in Figure 2A, in addition to the monomeric band,
both isoforms formed a prominent band, at a higher molecular
weight (80 kDa), representing the homodimers in the cell
lysates treated with the cross-linker. The dimeric form was
not detected when the cells were not treated with DSS,
suggesting that they were specific signals. To obtain indepen-
dent evidence for the observed dimerization, we have used
expression constructs that encode proteins with distinct
epitope-tags and used them for the pull-down experiments.
For this, COS-7 cells were co-transfected with expression con-
structs encoding Myc/His-tagged laf-331 and FLAG-tagged
laf331, Myc/His-tagged laf331 and FLAG-tagged laf317, or
Myc/His-tagged laf317 and FLAG-tagged laf317, and the
cell lysates were processed for pull downs using Nickel
resins followed by immunoblotting (Fig. 2B). Indeed, co-
precipitation was observed in lysates prepared from cells
that had expressed the same isoform with two distinct tags,
or both isoforms each with a unique tag, confirming that iso-
forms laf331 and laf317 physically interact with themselves
and with each other, thereby suggesting the presence of
homo- and heterodimeric forms of laforin phosphatase
(Fig. 2B). Control pull-down with Nickel resin in a lysate
that had the FLAG-tagged protein but not the Myc-tagged
protein confirmed the specificity of these assays (Fig. 2B).
To further validate the heterodimerization property of these
isoforms, laf331 and laf317 expression constructs with Myc/
His-tag and FLAG tag, respectively, were co-expressed in
COS-7 cells and the poly-histidine-tagged laf331 was pulled-
down using Ni-affinity resins (see Materials and Methods).
Upon DSS-mediated chemical cross linking, isoform laf317,
which should have been pulled-down by laf331, showed a
higher molecular weight corresponding to the heterodimers
(80 kDa) in addition to a monomeric band (Fig. 2C). This
dimeric form was detected both by anti-Myc and anti-FLAG
antibodies, thus establishing the presence of heterodimers
(Fig. 2C). Laf317 and laf331 showed significant overlap for
Figure 1. Domain organization and subcellular localization patterns for laforin
isoforms. (A) Schematic diagram showing the two differentially spliced tran-
scripts of the EPM2A gene, and the encoded proteins. For the transcripts,
boxes denote the exons, and the filled blocks are the 50- and 30-untranslated
regions (UTRs). Transcript-1 encodes a 331 amino acid long protein, named
laf331, and transcript-2 encodes a 317 amino acid long protein, named
laf317. The relative positions of the two domains of laforin, carbohydrate-
binding domains (CBD) and dual-specificity phosphatase domain (DSPD),
are also shown. The two domains are present in both isoforms. The unique
sequence at the carboxyl-terminal of the two isoforms is identified by the
‘hatched’ box. (B) A schematic diagram showing the carboxyl terminal of
laf331 and laf317 and the amino acid sequence of unique regions. (C) Repre-
sentative images of COS-7 cells showing the localization pattern of laf331 and
laf317. For this, COS-7 cells were transiently transfected with expression con-
structs that code for Myc-tagged laf331 or laf317 and processed for immuno-
fluorescence staining using anti-myc antibody. Scale bar, 10 mm.
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fluorescence staining pattern when co-expressed in COS-7
cells, and the subcellular localization pattern of laf317 was
not affected when co-expressed with laf331 (Fig. 3E–G).
Laf317 is an inactive phosphatase that competes with
laf331 for the substrate and regulates the activity
of laf331 by forming heterodimers
We and others have shown earlier that laf331 is a dual-
specificity phosphatase (7,9). In order to test whether laf317
exhibits phosphatase activity or not, COS-7 cells were transi-
ently transfected with the construct that codes for Myc/His-
tagged laf317 and purified the proteins using Ni-affinity
resins. Affinity purified products from COS-7 cells that
express Myc/His-tagged laf331 or an empty vector were
used as positive and negative controls, respectively. The resin-
bound proteins were used for the phosphatase assay with the
chromogenic substrate, para-nitrophenyl phosphate (pNPP)
(Fig. 4A). As demonstrated earlier (7), laf331 showed robust
phosphatase activity with pNPP; however, laf317 did not
show appreciable levels of activity with pNPP under identical
assay conditions, and the absorbance was similar to the assay
done with resins derived from the vector transfected cells,
suggesting that laf317 could perhaps be an inactive phospha-
tase (Fig. 4A).
Since laf317 interacted with laf331, we next checked
whether the laf317–laf331 heterodimeric form would be an
enzymatically active complex or not. For this, we transiently
over-expressed Myc/His-tagged or FLAG-tagged laf317 and
laf331—either together or separately as indicated in
Figure 3B, and purified them using affinity resins. The resin
bound proteins were tested for the phosphatase activity with
pNPP. As a control, we have used a phosphatase inactive
mutant of laf331, C266S (9,19), to establish the specificity
of the assay conditions (Fig. 4B). These experiments were
done in triplicate to account for any variations in the exper-
imental conditions. The presence of homo- and heterodimeric
forms of laforin isoforms in the pulled down products was
confirmed by immunoblotting with anti-Myc and anti-FLAG
antibodies. As shown in Figure 4B, the laf331 homodimer,
as expected, has shown robust phosphatase activity. However,
the homodimeric forms of laf331 C266S mutant or laf317 did
not show any appreciable level of activity. Furthermore, the
activity of laf331-Myc/His, as heterodimer with FLAG-
laf317, was reduced to nearly 60% to that of laf331 homodi-
mer (Fig. 4B). Since laf317 was pulled-down using His-tagged
laf331, the observed difference in the activity could be either
Figure 2. The two isoforms of laforin interact with each other and form
homodimers as well as heterodimers. (A) Laforin isoforms, laf331 and
laf317, over-expressed in COS-7 cells were treated (þ) or not treated (2)
with the cross-linker DSS, resolved in SDS–PAGE and detected by immuno-
blotting. Anti-laforin antibody detected a band at around 80 kDa, representing
the dimeric form for both laf331 and laf317 (identified by an arrow head) in
the samples that were treated with DSS. The monomeric form (45 kDa;
identified by an arrow) was present both in DSS-treated and -untreated
samples. (B) COS-7 cells were transiently co-transfected with expression con-
structs as indicated, and processed for pull down (PD) using nickel affinity
resin and by immunoblot (IB) analysis using anti-FLAG antibody. Cells that
were expressing only the FLAG-tagged protein were processed in parallel as
negative control (last lane). The PD products and the whole cell lysates
(WCL) were used for the IB detection. (C) To establish that laf331–laf317
heterodimer indeed forms, lysates from COS-7 cells that were expressing
Myc/His-tagged laf331 and FLAG-tagged laf317 were processed for affinity
purification using Ni-resin. The purified protein samples were either treated
or not treated with DSS, resolved in the same gel, transferred to the membrane
and the same blot was probed with anti-Myc, and after stripping, with anti-
FLAG antibodies. The higher molecular weight band (dimeric form identified
by an arrowhead) detected by the anti-Myc antibody was also detected by the
anti-FLAG antibody, thus establishing the presence of laf331–laf317 dimeric
complex. The monomeric forms are identified by an arrow.
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due to the laf331–laf317 heterodimers, or due to the presence
of lower levels of laf331 homodimers in the pulled down pro-
ducts. We reasoned that the latter possibility is likely, because,
in our pull-down assays, laf331 had consistently showed
higher affinity to itself when compared with laf317 (see
Fig. 4B). We have, therefore, used laf317-Myc/His for the
pull-down of laf331-FLAG and checked the activity of this
complex with pNPP (Fig. 4B). Since laf317 dimer is an inac-
tive phosphatase, pNPP activity if detected for this pull-down
product should come from the laf331–laf317 heterodimers.
While laf317–laf331 heterodimers were indeed present in
the pull-down products, this complex did not show detectable
levels of phosphatase activity (Fig. 4B). This observation
suggests that the laf331–laf317 heterodimer is an inactive
complex. In these assays, we believe that the heterodimers
were stable and did not dissociate to form homodimers
because, laf331-FLAG that were pulled with the His-tagged
laf317 or the laf331 mutant C266S should have shown some
activity when assayed with pNPP if it were the case. We there-
fore next examined whether laf317 would compete with laf331
for the substrate in vitro. To test this possibility, we mixed
increasing amounts of purified laf317 dimers with constant
amount of laf331 dimers and checked for the phosphatase
activity with pNPP as the substrate. As shown in Fig. 4C,
increasing concentrations of laf317 progressively diminished
the phosphatase activity displayed by laf331 in a dose-
dependent manner, suggesting that laf317 could possibly
compete for the substrate by binding to, and/or preventing
its dephosphorylation by laf331.
Laf317 does not bind to glycogen in vitro
We and others have shown that the purified laf331 binds to
glycogen in vitro (11,20). Laf331 also binds to Lafora polyglu-
cosan bodies (11,21), and has been shown to dephosphorylate
carbohydrate complexes (22). We were, therefore, curious to
check whether laf317 would bind to glycogen or not. For
this, Myc/His-tagged laf317 and laf331 were expressed separ-
ately in COS-7 cells, purified using Ni-resins and tested for
their affinity towards glycogen particles in vitro (see
Fig. 5A). As demonstrated earlier, laf331 sedimented with gly-
cogen in the pellet fraction, establishing its strong affinity
towards the glycogen-like complexes (Fig. 5A). Laf317, on
the other hand, was found in the supernatant fraction,
suggesting its lack of affinity towards glycogen particles
(Fig. 5A). Because laf331 forms dimer, and that the dimeric
form is active as a phosphatase, we have also tested whether
the observed glycogen affinity for laf331 is dependent upon
its dimerization. For this, we co-expressed two constructs
that code for laf331-Myc/His and FLAG-laf331 respectively,
purified the dimers using Ni-affinity resins, and did the glyco-
gen binding assay (Fig. 5B). While Myc-tagged laf331 was
seen both in the glycogen pellet and supernatant fractions,
FLAG-tagged laf331 was seen only in the supernatant fraction.
Since the FLAG-tagged laf331 is expected to be present only
as a dimer in our pulled-down products, the absence of any
signal for FLAG epitope in the pellet fraction suggest that
homodimers of laf331 do not bind to glycogen in vitro and
the observed affinity could perhaps be restricted to the mono-
meric form. Since laf331 and laf317 form heterodimer, we
next checked whether the heterodimer would bind to glycogen
or not. For this, the purified heterodimers were incubated
with glycogen and checked for their affinity. As shown in
Figure 3. Laf317 co-localize with laf331 and malin, and form aggresome upon
proteasomal blockade. Laforin isoforms laf317 and laf331 were transiently
expressed in COS-7, either separately (A–D) or together (E–J), and were
either treated (B,D, H, I and J)) or untreated (A, C, E, F and G) with
MG132 for 12 h. Twenty-four hours post-transfection, cells were processed
for indirect immunofluorescence staining using appropriate antibodies.
Laf317 was also co-expressed with malin to see if they both co-localize
(K–P). For this, cells were treated either not treated (K, L and M) or
treated (N, O and P) with MG132 and processed for indirect immunofluores-
cence staining. For all the experiments, cells were counterstained with DAPI
to reveal nucleus. Arrows indicate aggresomal structures. Scale bar, 10 mm.
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Figure 5C, when the heterodimer was pulled using a tag
specific to laf331, a majority of laf331 was detected in the
supernatant fraction and a smaller fraction was seen in the
pellet fraction. However, laf317, which was pulled by
laf331, was detected only in the supernatant fraction,
suggesting that the laf331–laf317 heterodimer does not bind
to glycogen. This conclusion was further strengthened when
the heterodimer was pulled by laf317 and tested for its
affinity to glycogen; neither laf317 nor laf331 was seen in
the pellet fraction further strengthening the conclusion that
the laf331–laf317 heterodimer does not bind to glycogen
in vitro (Fig. 5C).
Malin interacts with and degrades laf317
Malin is known to co-localize, interact and degrade laf331
through the proteasomal system (4,5,23). Therefore, we were
interested in testing whether or not malin would interact
with and degrade laf317. For this, we co-expressed malin
with laf331 or laf317 in COS-7 cells and processed for
double immunofluorescence staining or for the pull down
assays using FLAG-affinity resins. Laf317 showed almost
complete overlap with malin in immunostaining, suggesting
that laf317 might occupy the same cellular compartment as
malin that allows for a physical interaction (Fig. 3K–M).
Laf331 is known to form aggresome, either on its own or
with malin, when cells were treated with a proteasomal
blocker (5). We therefore checked whether laf317 would
show the same property or not by treating the cells with
MG132—a proteasomal blocker. As shown in Figure 3A–D,
laf317 developed aggresome-like perinuclear aggregates
upon proteasome blockade when expressed alone, and when
expressed with laf331 or malin (Fig. 3H–J and N–P).
In order to check whether laf317 would physically interact
with malin or not, we have co-expressed FLAG-tagged
laf331 or laf317 with Myc/His tagged malin and pulled
laforin isoforms using anti-FLAG antibody. As shown in
Figure 6A, both isoforms of laforin were able to pull-down
malin, suggesting that, similar to laf331, laf317 could serve
as malin’s substrate. To test this possibility, we co-expressed
Figure 4. Laf317 is an inactive phosphatase that competes with laf331 for the substrate and regulates the activity of laf331 by forming a heterodimer. (A) Myc/
His-tagged laf331 or laf317 was transiently expressed in COS-7 cells, affinity purified using Nickel resin and the resin-bound protein was used for the phospha-
tase assay using pNPP. The pull-down product from the empty vector transfected (pcDNA) cells was used as negative control. Each bar represents the mean
average of three independent assays. The purity of the pulled-down protein in each experiment was examined by immunoblotting, as shown below the
graph. (B) In order to check whether the heterodimers of laf331–laf317 are active as a phosphatase or not, COS-7 cells were transiently transfected with
the expression construct as indicated and processed for the Ni-affinity resin pull-down assays. The purified proteins were used for the phosphatase assay
using the pNPP as substrate and the activity was plotted on the y-axis. Values shown are means of three independent reactions. The purity and expression
levels of the pulled-down proteins in each experiment were examined by immunoblotting, as shown below the graph. (C) In order to establish whether
laf317 would compete with laf331 for substrate binding, Myc/His-tagged laf331 and laf317 were expressed separately in COS-7 cells, affinity purified and
the two isoforms were mixed together in different ratios as indicated and assayed for phosphatase activity using pNPP. The value shown in each bar is
mean of three independent reactions, and is relative to the activity shown by laf331 alone. The volume of pulled-down product added to each reaction was
normalized by adding appropriate amount of resins from the lysates of cells transfected with the empty vector (pcDNA). Similarly, purity of the proteins
(laf331 and laf317) used for the assay was confirmed by immunoblotting, as shown below the graph. The fractional saturation of enzyme was calculated in
pilot experiments by testing various concentrations of pNPP in a reaction that had a fixed amount of enzyme. Thus, 25 mM concentration of pNPP was
found to be closer to the saturation level for the amount of purified laf331 used in the phosphates assay (data not shown).
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laf317 with wild-type malin, or with a catalytically inactive
mutant malin (C26S) (4,5) in COS-7 cells and evaluated the
relative levels of laf317. As a control experiment, in parallel,
cells expressing laf317 and wild-type malin were treated with
a proteasomal blocker (MG132) (Fig. 6B). Identical set of
experiments were also carried out with laf331, and the total
cell lysates were immunoblotted to detect the relative levels
of laf317 or laf331 (Fig. 6B). Laf317 showed significant
reduction in their cellular levels when expressed with the wild-
type malin when compared with those that were expressed
with the malin mutant, C26S (Fig. 6B). Significant increase
in the levels of misfolded proteins was observed when cells
co-expressing wild-type malin were treated with a proteasomal
inhibitor (MG132), suggesting that malin facilitates the degra-
dation of laf317 through the proteasomal system (Fig. 6B).
Identical results were also obtained for laf331, suggesting
that both the isoforms of laforin serve as substrates for
malin (Fig. 6B). To confirm whether malin show equal prefer-
ence to the laforin isoforms, or whether it prefers one over the
other, we expressed the catalytically inactive malin mutant
C26S with laf331 and laf317, and pulled malin and immuno-
blotted for laforin isoforms (Fig. 6C). While the intensity of
the signals for laf331 and laf317 was almost same in the
whole cell lysate, the intensity of signal for laf331 in the
pulled down product was almost two-fold higher than that of
laf317, suggesting that malin could display higher affinity
towards laf331 (Fig. 6C). Since the pull-down assays were
done by using a catalytically inactive malin, and were repeated
twice, we assume that the intensity of the signal corresponds to
the total protein available for interaction and does not rep-
resent the amount of product that ‘escaped’ malin-mediated
degradation.
Role of laf317 in LD pathology: effect of laf331-specific
mutations on laf317
Among the two known isoforms of laforin, laf331 is conserved
across the vertebrates (11). Splice variants of laforin are not
seen in mice or other mammalian species, and thus, laf317
appears to be unique to human (17, Dubey and Ganesh, unpub-
lished observations). Since laf317-specific mutations have
not yet been identified in LD patients, and because knockout
of laf331 led to the LD-like phenotype in mice (24), it
has been suggested that laf317 may not be relevant to LD
pathology in humans (1,17,18). With the demonstration
of formation of functional heterodimers between laf331 and
laf317 in the present study, we were tempted to check the
possibility of impairment in the interaction between a
mutant laf331 and the wild-type laf317. For this, we selected
two LD-associated mutations, Q319fs and L310W, and these
two mutations are intronic in the transcript that encodes
laf317 and, therefore, unlikely to alter the peptide sequence
of laf317 (17,18) (Fig. 7A). We created these mutations in
the laf331 coding sequence and expressed them in-frame to
a Myc/His-tag at the carboxyl terminal. We have examined
whether the two mutants would form homodimers by chemical
cross linking with DSS and evaluated the cross-linked
products by immunoblot analysis. As shown in Figure 7B,
both the mutants have formed a higher molecular weight
band in the cell lysates that were treated with the
cross-linker, suggesting that the mutant laf331 could form
homodimers with itself. We next checked the possibility
whether or not these mutants interact with laf317 or the
Figure 5. Laf331 binds to glycogen only as a monomeric form, whereas
laf317 does not bind to glycogen as a homodimer or as a heterodimer. (A)
Purified laf331 or laf317 protein was incubated in the presence (þ) or
absence (2) of glycogen, centrifuged, and the supernatant (S) and the pellet
(P) fractions were collected and subjected to immunoblot analysis using appro-
priate antibody. (B) In order to establish whether laf331 binds to glycogen as a
monomer or as a dimer, COS-7 cells were double transfected with plasmids
that code for FLAG-tagged laf331 and Myc/His-tagged laf331, the proteins
were purified using Ni-affinity resins, eluted from the resins and checked for
glycogen binding affinity as mentioned above. The same blot was used for
probing with anti-FLAG and anti-Myc antibodies. Control experiment
lacking the glycogen was carried out in parallel. (C) To check whether
laf317 would bind to glycogen as heterodimer with laf331, the isoforms
were expressed in COS-7 cells as indicated, affinity-purified using nickel
resin, eluted and checked for glycogen binding property as described above.
The proteins in the pellet (P) and supernatant (S) fractions were processed
for immunoblotting with anti-FLAG and anti-Myc antibodies. Control exper-
iment lacking the glycogen was carried out in parallel.
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wild-type laf331. For this, the mutants were co-expressed with
FLAG-tagged laf331 or laf317, pulled-down using Ni-resin
and detected using a tag-specific antibody. As can be seen
in Figure 7C, laf331, but not laf317, was pulled-down by
Q319fs and L310W mutants, suggesting that these mutations
have abolished the interaction between laf331 and laf317.
Thus, in these patients, the formation of laf331–laf317 hetero-
dimers is unlikely to take place.
DISCUSSION
Alternative splicing in the human EPM2A gene gives rise to
two mRNA variants. Here we demonstrate that the two
isoforms of laforin, coded by the transcript variants, are
functionally distinct from each other. Laf317 is an inactive
phosphatase and acts as a dominant-negative regulator for
the phosphatase activity of laf331. We further show that
Figure 6. Malin interacts with and degrades laf317. (A) To check the interaction of malin with laf317, COS-7 cells were co-transfected with constructs that code
for Myc-tagged malin and FLAG-tagged laf317, and processed for immunoprecipitation assays using anti-FLAG resin. Cells that were transfected with
laf331-Myc and FLAG-malin were processed in parallel as positive controls. The pulled-down products (IP) and whole cell lysates (WCL) were immunoblotted
(IB) with anti-FLAG and anti-Myc antibodies. (B) To check whether malin promotes degradation of laf317, COS-7 cells were co-transfected with expression
constructs for wild-type or mutant malin and laforin isoforms as indicated, and the cellular levels of laf317 or laf331 was established by immunoblotting. As a
control, cells that expressed wild-type malin and laf331 or laf317 were treated with MG132 and processed in parallel. The signal intensity of laforin isoforms was
measured and plotted as a bar diagram. Values shown are mean of two independent experiments, and an asterisk mark indicates the significant decrease in the
signal intensity when compared with the other two lanes (mutant malin or the MG132 treatment) as calculated by paired t-test. Immunoblotting for g-tubulin
levels served as loading control. (C) To check relative affinity of laf331 and laf317 towards malin, COS-7 cells were transiently transfected with constructs that
express Myc/His-tagged mutant malin (C26S) with GFP-laf331 and FLAG-laf317 and processed for Ni-affinity pull-down assays. The whole cell lysate (WCL)
and the pulled-down (PD) samples were run in the same gel and processed for immunoblotting with anti-laforin antibody that detects both isoforms of laforin
(identified by arrows on the left). The relative intensity of signals detected for the whole cell lysate and the pulled-down product was estimated and plotted. The
value in the bar represents mean of two independent experiments, and an asterisk mark indicates the significant decrease in the signal intensity when compared
with the whole cell lysate (WCL). That the GFP-tag did not alter the affinity of laf331 towards malin was established by pull-down assays (pilot experiments) in
which malin was unable to pull GFP when co-expressed and malin was able to pull FLAG-tagged laf331 and GFP-tagged laf331 with equal affinity when all
three were expressed together (data not shown). Numbers given on the y-axis in both (B) and (C) represent arbitrary values (AV).
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each isoform of laforin can form a homodimer with itself or a
heterodimer with the other. The pull-down and cross-linking
assays used in the present investigation for demonstrating
the dimerization potential of laf317 and laf331 are indirect
approaches, and therefore one cannot exclude the possibility
that the interaction with itself or with the other isoform
requires additional protein(s) to form the complex. Nonethe-
less, we believe, for the following reasons, that the laforin
isoforms might directly interact with each other and form
heterodimers; (i) the ‘dimeric band’ detected in the immuno-
blot for the cross-linked samples for both isoforms are of the
expected size for the dimers, (ii) a recent study has demon-
strated that the bacterially expressed laf331 dimerize and is
enzymatically active (20), and (iii) laf331 and laf317 interact
with each other in a yeast two-hybrid screen (our unpublished
observations). Similar to laforin, functional isoforms of
protein phosphatases that result from differential splicing are
known in the literature. For example, differential dimerization
properties of splice variants negatively regulate the activity of
CD45, PTP1 and PPARg1 phosphatases and their signaling
cascades (25–28).
We cannot yet ascribe any physiological significance to the
homo- and the heterodimerization properties of laf331 and
laf317 because the phosphatase assays employed in the
present study were limited to a synthetic substrate. Since
dimerization is required for the phosphatase activity of
laf331, we nonetheless believe that some as yet unidentified
additional stimuli may affect dimerization property and modu-
late the activity of laf331 to the desired level. One of them
could be the glycogen level. Since the dimeric form of
laf331 does not bind to glycogen in vitro, we speculate that
the activity of laf331 could be modulated by the relative
levels of free versus glycogen-bound forms of laf331. Thus,
the monomeric laf331 that is bound to the glycogen could
be an inactive species; conversely, the affinity towards glyco-
gen could be lower for the enzymatically active dimeric form
of laf331. A support for this notion comes from the report of
Wang et al. (20), wherein, they have shown that the phospha-
tase activity of laf331 was profoundly inhibited by the addition
of polysaccharides. This binding, and hence the dimerization
process, is likely to be dynamic in nature because laf331 is
also known to remove the phosphate groups in complex
polysaccharides (22,29), and loss of laforin lead to increased
phosphorylation of glycogen in laforin deficient mice (29).
However, it is unclear as of now as to whether the dimeric
laf331 would dephosphorylate the phospho groups before
binding to the polysaccharide moieties as a monomeric
form, or whether its affinity towards polysaccharides as mono-
meric form would facilitate its physical interaction leading
to dimerization and eventual dephosphorylation of polysac-
charides. Clearly, the dimerization property of laf331, and
laf317, in relation to glycogen affinity needs to be studied
further under in vivo conditions.
Our observations that laf317 does not bind to glycogen are
intriguing because the carbohydrate binding domain is located
in the amino-terminal of the peptide and its sequences are not
altered by the differential splicing of the transcript that
encodes laf317. It is likely, therefore, that the unique carboxyl-
terminal domain affects the conformation of laf317 such that
laf317 is unable to bind to the glycogen. Indeed missense
mutations in the phosphatase domain are known to affect the
glycogen affinity of laf331 (10), suggesting that the laforin-
glycogen interaction is conformation-dependent. Clearly,
structural studies would provide insights into the confor-
mational changes of the isoforms resulting from the alternative
splicing.
Figure 7. LD-associated mutations affect interaction between laf331 and
laf317. (A) Schematic diagram showing the carboxyl-terminal unique
sequence of laf331 and laf317, and the positions of the two mutations
(L310W and Q319fs) whose effects are restricted to laf331. (B) The wild-type
form and the two mutant forms of laf331 were transiently expressed in COS-7
cells, treated (þ) or not treated (2) with DSS and subjected to immunoblot-
ting with anti-laforin antibody. Similar to the wild-type form, both the mutants
formed homodimers upon DSS treatment (identified by an arrowhead). The
monomeric forms are identified by an arrow. (C) To check the physical inter-
action between laf331 mutants and laf317, COS-7 cells were transiently trans-
fected with expression constructs as indicated and processed for pull-down
assays using Ni-affinity resin. Interactions between proteins were tested by
probing the pull-down products (PD) and the whole cell lysates (WCL) with
appropriate antibodies. Cells that were transfected with a construct that
codes for the FLAG-tagged protein and an empty vector served as negative
controls.
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Although we have not yet checked the temporal expression
pattern of the two isoforms of laforin in various human tissues,
we have shown here that if present together, laf317 affects the
phosphatase activity of laf331 in a dominant-negative manner,
at least with a synthetic substrate tested. This property of
laf317 is analogous to the one described for a splice variant
of PPARg1 in activating a signaling cascade (27). Protein iso-
forms that are encoded by alternative splice variants that exert
repressive activity over other species are known for many pro-
teins, especially in the class of nuclear receptors (30–32). The
protein species of splice variants with distinctive, overlapping
and in some instances opposite functions to the major isoforms
of a gene product may serve as a general mechanism by which
the cellular functions of a protein complex can be modulated
in response to various physiological signals. For example,
the laforin-mediated cellular pathway could be altered by vari-
ations in the ratio of laf331–laf317 isoforms because the
dephosphorylation of a laforin substrate might depend upon
the cellular levels of laf331 homodimers. Thus, an increase
in the levels of laf317 variant could sequester laf331 into
the heterodimer, making it an enzymatically inactive complex.
It has been shown previously that the expression levels of
laf317 transcript in human brain tissues was a few fold
lower when compared with that of laf331 (16). It is likely
that the physiological signals that modulate the cellular
levels of laforin isoforms might act either at the level of tran-
script (splicing) or protein (synthesis and/or degradation). We
show here that one of such factors could be the malin ubiquitin
ligase, because malin interacts with and degrades both laf331
and laf317. In this regard, it is intriguing to note that, despite
almost complete co-localization with laf317 (nuclear and cyto-
plasmic localization), malin displays higher affinity towards
laf331 though the latter is restricted to the cytoplasm in local-
ization. The unique carboxyl-terminal of laf317 might alter its
interaction/affinity with malin because missense mutations in
laf331 are known to impair the interaction between laf331
and malin (4,14). It is likely, therefore, that the malin-
mediated protein turn-over rates could be different for the
monomers of laf331 and laf317, their dimers and for the
laf331–laf317 heterodimers. The relative ratios of these
different forms in cellular milieu could also be altered by cel-
lular signals, and thus, malin could prefer one complex over
the other for the degradation. Thus malin, by selectively
degrading a given isoform or its complex, might either
unmask or promote the inhibitory effect of laf317 over
laf331. On the other hand, laforin isoforms could also alter
the cellular functions of malin. We have shown recently that
laf331 co-localize with malin in the aggresome structures,
and proposed that the laf331–malin complex might enhance
the ubiquitination of its substrates and facilitate their efficient
degradation (5). We show here that both laf331 and laf317
target aggresome upon proteasome blockade, and that both
isoforms co-localize with malin. Thus, as it has been demon-
strated here for the phosphatase activity and glycogen affinity,
laf317 could compete with laf331 and block the degradation of
a target protein by the malin–laf331 complex. For example,
malin is known to degrade PTG in a laf331-dependent
manner and thus loss of laf331 leads to excessive glycogen
deposition (13,14). It would, therefore, be of interest to
check whether laf317 competes with laf331 for the interaction
with PTG and prevents its degradation or not. Intriguingly, it
was shown that a catalytically inactive mutant of laf331 can
promote the degradation of PTG (13,14). Therefore it is
likely that laf317 would do the same function if it interacts
with PTG, because the phosphatase activity is not likely to
be required for this process. It should be noted, however,
that a majority of these experiments was carried out in
non-human cell lines which do not have laf317 isoform and
hence the relevance of these findings should be tested in
human cell lines to understand the role of laf317 in PTG
stability. A second possibility could be that laf317 competes
with, and blocks laf331 from dephosphorylating the glycogen
complex, because laf331 is known to remove phosphate
groups from glycogen (22,29), and the phospho content of
glycogen has gone up several fold in the laforin deficient
mice (29).
A large number of mutations have been identified in the
EPM2A gene that are known to or expected to affect the
functional properties of laforin protein (reviewed in 1).
Among these, the two mutations, Q319fs and L310W,
characterized in the present study offer novel insights into
the LD pathogenesis (18). Since the effects of these
mutations are restricted to the laf331 isoform, it was
suggested that the isoform laf317 might not have any
relevance to LD pathogenesis (17,18). We show here that
both the mutations affected the interaction between mutant
laf331 and laf317, thereby suggesting that, although the
mutation is specific to laf331, the functional properties of
the laf331–laf317 heterodimers might have been affected
in these patients. Thus, defects in one isoform are likely to
affect at least some of the functions of the other isoform.
In this regard, it is interesting to note that unlike laf331,
laf317 is localized in the nucleus as well. Thus, laf317
might have some unique functions that are not likely to be
compensated by laf331. Since mutations that exclusively
affect laf317 are yet to be identified, the physiological
impact of loss of laf317 in neurological functions is difficult
to speculate. It would be of interest, therefore, to develop
appropriate models to explore the shared and distinct func-
tions of laforin isoforms and their regulatory roles on malin-
mediated cellular cascade. Ongoing studies in our laboratory
are expected to shed light on some of these issues.
MATERIALS AND METHODS
Expression constructs
The expression vectors containing Myc- or GFP-tagged
wild-type or mutant forms of laforin or malin were
described previously (5,18,19). For FLAG-tagged con-
structs, the coding region of laf331 was cloned in-frame
with a FLAG epitope in a pcDNA vector. For laf317
expression constructs, the image clone 266552, obtained
from Open Biosystem, was used as a template for PCR
amplification and cloned into expression constructs as
described previously (16). The laforin mutant clone,
Q319fs, was generated by creating the mutation in coding
regions of laf331 by site-directed mutagenesis as described
earlier (7). The mutant clone L310W was described in one
of our previous studies (18).
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Cell culture and transfections
COS-7 cells were grown in Dulbecco’s modified Eagle’s
medium (Sigma-Aldrich India Pvt Ltd) supplemented with
10% (vol/vol) fetal calf serum, 100 U/ml penicillin and
100 mg/ml streptomycin. All cells were grown at 378C in
5% CO2. Transfections were performed using LipofectAMINE
2000 (Invitrogen Inc, USA) or Escort V (Sigma-Aldrich India
Pvt Ltd) transfection reagent according to the manufacturer’s
protocol. Cells were harvested at 24 h (LipofectAMINE
2000) or 36 h (Escort V) post-transfection, as recommended
by the manufacturer.
Immunostaining and antibodies
COS-7 cells, grown on gelatin-coated sterile glass coverslips,
were fixed and processed for immunofluorescence microscopy
essentially as described earlier (5). Cells were fixed with
paraformaldehyde (4%), permeabilized (0.05% Tween 20)
and subsequently incubated with primary and secondary anti-
bodies. For nuclear staining, fixed cells were incubated with
10 mM 40, 6-diamidino-2-phenylindole (DAPI). Fluorescence
images were obtained using a fluorescence microscope
(Nikon Eclipse 80i, Japan) with 40 objective lens and
were processed using ImageExpress software (Media Cyber-
netics, USA). Representative images were then imported to
Photoshop (Adobe) for processing. The following antibodies
were used in the present study; anti-Myc (Cell Signaling Tech-
nology, USA), anti-g-tubulin, anti-FLAG (both from
Sigma-Aldrich India Pvt Ltd) and anti-laforin antibody (5).
Secondary antibodies were obtained from Jackson Immuno
Research Inc. (USA).
DSS cross-linking
COS-7 cells that had expressed desired proteins were treated
with 5 mM DSS (Pierce, Rockford, USA) for 2 h at 48C, and
then the activity was quenched with 25 mM Tris-Cl (pH 7.5),
as recommended by the manufacturers. The cells were then
washed briefly in ice-cold PBS, lysed in Laemmli buffer and
the lysates were processed for immunoblotting.
Immunoblotting analysis
Protein samples were run on a 10% SDS–PAGE and
transferred onto a nitrocellulose filter (MDI, India) as
described previously (5). After blocking with 5% non-fat
dry milk powder, the membranes were processed through
sequential incubations with primary antibody followed by
secondary antibody. Immunoreactive proteins on the filter
were visualized using a chemiluminscent detection kit
(SuperSignal West PICO, Pierce, USA). For quantitation,
the signal intensity in the digital images was measured
using the Quantity One Discovery Series software of
Bio-Rad Laboratories.
Pull-down assays
To establish the physical interaction between laforin isoforms
and other target proteins, we have used two different
approaches. In one, the lysates of cells that had over-expressed
poly-histidine-tagged protein was incubated with Ni-affinity
resin (Sigma-Aldrich India Pvt Ltd) for 2 h at 48C and pro-
cessed for pull-down assays as recommended by the manufac-
turer. In the other method, FLAG-tagged proteins were
selectively captured using the anti-FLAG M2 affinity gels
(Sigma-Aldrich India Pvt Ltd) as recommended by the manu-
facturer. Pulled-down products were detected by immunoblot-
ting using specific antibodies.
Phosphatase activity assay
Histidine-tagged laf331, its mutants, laf317, or their combi-
nations as specified were transiently expressed in COS-7
cells and purified using nickel affinity resin (Sigma-Aldrich
India Pvt Ltd) as per the manufacturer’s protocol. Around
100 ng of the bead-bound proteins were used for each of the
phosphatase assay. The reaction was performed in 75 ml reac-
tion buffer (50 mM HEPES pH 6.0, 50 mM NaCl, 5 mM EDTA
and 50 mM b-mercaptoethanol) containing 25 mM of pNPP
and the reaction was carried out at 378C for 30 min. The reac-
tion was arrested with the addition of NaOH and absorbance
was taken at 405 nm. A fraction of the bead-bound protein
was boiled in Laemmli buffer and used for immunoblot analy-
sis. The fractional saturation of enzyme was calculated in pilot
experiments by testing various concentrations of pNPP in a
reaction that had a fixed amount of enzyme. Thus, 25 mM con-
centration of pNPP was found to be closer to the saturation
level for the amount of laf331 protein used in the assay
(data not shown).
Glycogen binding assay
Histidine-tagged laf331 or laf317, or their combinations as
specified, were transiently expressed in COS-7 cells and puri-
fied using nickel affinity resin (Sigma-Aldrich India Pvt Ltd)
as per the manufacturer’s protocol. The bead-bound proteins
were eluted in glycogen binding assay buffer (50 mM Tris
pH 7.5, 150 mM NaCl, 0.1% b-mercaptoethanol and 0.1 mg/ml
BSA) in the presence of 20 mM imidazole. The eluted proteins
were then dialyzed overnight in the glycogen binding buffer
lacking imidazole and processed for glycogen binding assay
as described previously (11). For each assay, 10 mg/ml glyco-
gen was used and the protein was incubated with glycogen at
48C for 30 min and then centrifuged at 17 000 g for 90 min at
48C to get supernatant and pellet fractions. Protein samples
derived from these two fractions were subjected to immuno-
blotting to assess the affinity of laforin isoforms towards
glycogen.
FUNDING
Department of Science and Technology, and Department of
Biotechnology, Government of India (Sponsored Research
Grants) to S.G.; Council of Scientific and Industrial Research,
Government of India (Research Fellowships) to D.D.
Conflict of Interest statement. None declared.
Human Molecular Genetics, 2008, Vol. 17, No. 19 3019
 by guest on January 10, 2017
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
REFERENCES
1. Ganesh, S., Puri, R., Singh, S., Mittal, S. and Dubey, D. (2006) Recent
advances in the molecular basis of Lafora’s progressive myoclonus
epilepsy. J. Hum. Genet., 51, 1–8.
2. Delgado-Escueta, A.V., Ganesh, S. and Yamakawa, K. (2001) Advances
in the genetics of progressive myoclonus epilepsy. Am. J. Med. Genet.,
106, 129–138.
3. Chan, E.M., Young, E.J., Ianzano, L., Munteanu, I., Zhao, X.,
Christopoulos, C.C., Avanzini, G., Elia, M., Ackerley, C.A., Jovic et al.
(2003) Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat.
Genet., 35, 125–127.
4. Gentry, M.S., Worby, C.A. and Dixon, J.E. (2005) Insights into Lafora
disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the
degradation of laforin. Proc. Natl Acad. Sci. USA, 102, 8501–8506.
5. Mittal, S., Dubey, D., Yamakawa, K. and Ganesh, S. (2007) Lafora
disease proteins malin and laforin are recruited to aggresomes in response
to proteasomal impairment. Hum. Mol. Genet., 1, 753–762.
6. Minassian, B.A., Lee, J.R., Herbrick, J.A., Huizenga, J., Soder, S.,
Mungall, A.J., Dunham, I., Gardner, R., Fong, C.Y., Carpenter, S. et al.
(1998) Mutations in a gene encoding a novel protein tyrosine phosphatase
cause progressive myoclonus epilepsy. Nat. Genet., 2, 171–174.
7. Ganesh, S., Agarwala, K.L., Ueda, K., Akagi, T., Shoda, K., Usui, T.,
Hashikawa, T., Osada, H., Delgado-Escueta, A.V. and Yamakawa, K.
(2000) Laforin, defective in the progressive myoclonus epilepsy of Lafora
type, is a dual-specificity phosphatase associated with polyribosomes.
Hum. Mol. Genet., 9, 2251–2261.
8. Ganesh, S., Delgado-Escueta, A.V., Suzuki, T., Francheschetti, S., Riggio,
C., Avanzini, G., Rabinowicz, A., Bohlega, S., Bailey, J., Alonso, M.E. et
al. (2002) Genotype–phenotype correlations for EPM2A mutations in
Lafora’s progressive myoclonus epilepsy: exon 1 mutations associate with
an early-onset cognitive deficit subphenotype. Hum. Mol. Genet., 11,
1263–1271.
9. Wang, J., Stuckey, J.A., Wishart, M.J. and dixon, J.E. (2002) A unique
carbohydrate binding domain targets the lafora disease phosphatase to
glycogen. J. Biol. Chem., 25, 2377–2380.
10. Ferna´ndez-Sa´nchez, M.E., Criado-Garcı´a, O., Heath, K.E., Garcı´a-Fojeda,
B., Medran˜o-Ferna´ndez, I., Gomez-Garre, P., Sanz, P., Serratosa, J.M. and
Rodrı´guez de Co´rdoba, S. (2003) Laforin, the dual-phosphatase
responsible for Lafora disease, interacts with R5(PTG), a regulatory
subunit of protein phosphatase-1 that enhances glycogen accumulation.
Hum. Mol. Genet., 1, 3161–3171.
11. Ganesh, S., Tsurutani, N., Suzuki, T., Hoshii, Y., Ishihara, T.,
Delgado-Escueta, A.V. and Yamakawa, K. (2004) The
carbohydrate-binding domain of Lafora disease protein targets Lafora
polyglucosan bodies. Biochem. Biophys. Res. Commun., 313, 1101–1109.
12. Liu, Y., Wang, Y., Wu, C., Liu, Y. and Zheng, P. (2006) Dimerization of
Laforin is required for its optimal phosphatase activity, regulation of
GSK3beta phosphorylation and Wnt signaling. J. Biol. Chem., 17,
34768–34774.
13. Worby, C.A., Gentry, M.S. and Dixon, J.E. (2008) Malin decreases
glycogen accumulation by promoting the degradation of protein targeting
to glycogen (PTG). J. Biol. Chem., 15, 4069–4076.
14. Solaz-Fuster, M.C., Gimeno-Alcan˜iz, J.V., Ros, S., Fernandez-Sanchez,
M.E., Garcia-Fojeda, B., Criado-Garcia, O., Vilchez, D., Dominguez, J.,
Garcia-Rocha, M., Sanchez-Piris, M. et al. (2008) Regulation of glycogen
synthesis by the laforin-malin complex is modulated by the
AMP-activated protein kinase pathway. Hum. Mol. Genet., 1, 667–678.
15. Vilchez, D., Ros, S., Cifuentes, D., Pujadas, L., Valle`s, J., Garcı´a-Fojeda,
B., Criado-Garcı´a, O., Ferna´ndez-Sa´nchez, E., Medran˜o-Ferna´ndez, I.,
Domı´nguez, J. et al. (2007) Mechanism suppressing glycogen synthesis in
neurons and its demise in progressive myoclonus epilepsy. Nat. Neurosci.,
10, 1407–1413.
16. Ganesh, S., Suzuki, T. and Yamakawa, K. (2002) Alternative splicing
modulates subcellular localization of laforin. Biochem. Biophys. Res.
Commun., 15, 1134–1137.
17. Ianzano, L., Young, E.J., Zhao, X.C., Chan, E.M., Rodriguez, M.T.,
Torrado, M.V., Scherer, S.W. and Minassian, B.A. (2004) Loss of
function of the cytoplasmic isoform of the protein laforin (EPM2A)
causes Lafora progressive myoclonus epilepsy. Hum. Mutat., 23,
170–176.
18. Singh, S., Satishchandra, P., Shankar, S.K. and Ganesh, S. (2008) Lafora
disease in the Indian population: EPM2A and NHLRC1 gene mutations
and their impact on subcellular localization of laforin and malin. Hum.
Mutat., 29, E1–E12.
19. Ganesh, S., Tsurutani, N., Suzuki, T., Ueda, K., Agarwala, K.L., Osada,
H., Delgado-Escueta, A.V. and Yamakawa, K. (2003) The Lafora disease
gene product laforin interacts with HIRIP5, a phylogenetically conserved
protein containing a NifU-like domain. Hum. Mol. Genet., 15,
2359–2368.
20. Wang, W. and Roach, P.J. (2004) Glycogen and related polysaccharides
inhibit the laforin dual-specificity protein phosphatase. Biochem. Biophys.
Res. Commun., 17, 726–730.
21. Chan, E.M., Ackerley, C.A., Lohi, H., Ianzano, L., Cortez, M.A.,
Shannon, P., Scherer, S.W. and Minassian, B.A. (2004) Laforin
preferentially binds the neurotoxic starch-like polyglucosans, which form
in its absence in progressive myoclonus epilepsy. Hum. Mol. Genet., 13,
1117–1129.
22. Worby, C.A., Gentry, M.S. and Dixon, J.E. (2006) Laforin, a dual
specificity phosphatase that dephosphorylates complex carbohydrates.
J. Biol. Chem., 13, 30412–30418.
23. Lohi, H., Ianzano, L., Zhao, X.C., Chan, E.M., Turnbull, J., Scherer, S.W.,
Ackerley, C.A. and Minassian, B.A. (2005) Novel glycogen synthase
kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy.
Hum. Mol. Genet., 15, 2727–2736.
24. Ganesh, S., Delgado-Escueta, A.V., Sakamoto, T., Avila, M.R.,
Machado-Salas, J., Hoshii, Y., Akagi, T., Gomi, H., Suzuki, T., Amano,
K. et al. (2002) Targeted disruption of the Epm2a gene causes formation
of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy
and impaired behavioral response in mice. Hum. Mol. Genet., 11,
1251–1262.
25. Xu, Z. and Weiss, A. (2002) Negative regulation of CD45 by differential
homodimerization of the alternatively spliced isoforms. Nat. Immunol., 3,
764–771.
26. Toledano-Katchalski, H., Tiran, Z., Sines, T., Shani, G., Granot-Attas, S.,
Hertog, J.D. and Elson, A. (2003) Dimerization in vivo and inhibition of
the nonreceptor form of protein tyrosine phosphatase epsilon. Mol. Cell.
Biol., 23, 5460–5471.
27. Kim, H.J., Woo, I.S., Kang, E.S., Eun, S.Y., Kim, H.J., Lee, J.H., Chang,
K.C., Kim, J.H. and Seo, H.G. (2006) Identification of a truncated
alternative splicing variant of human PPARgamma1 that exhibits
dominant negative activity. Biochem. Biophys. Res. Commun., 347,
698–706.
28. Sabatino, L., Casamassimi, A., Peluso, G., Barone, M.V., Capaccio, D.,
Migliore, C., Bonelli, P., Pedicini, A., Febbraro, A., Ciccodicola, A. and
Colantuoni, V. (2005) A novel peroxisome proliferator-activated receptor
gamma isoform with dominant negative activity generated by alternative
splicing. J. Biol. Chem., 15, 26517–26525.
29. Tagliabracci, V.S., Turnbull, J., Wang, W., Girard, J.M., Zhao, X., Skurat,
A.V., Delgado-Escueta, A.V., Minassian, B.A., Depaoli-Roach, A.A. and
Roach, P.J. (2007) Laforin is a glycogen phosphatase, deficiency of which
leads to elevated phosphorylation of glycogen in vivo. Proc. Natl Acad.
Sci. USA, 4, 19262–19266.
30. Lu, N.Z. and Cidlowski, J.A. (2006) Glucocorticoid receptor isoforms
generate transcription specificity. Trends Cell. Biol., 16, 301–307.
31. Duma, D., Jewell, C.M. and Cidlowski, J.A. (2006) Multiple
glucocorticoid receptor isoforms and mechanisms of post-translational
modification. J. Steroid. Biochem. Mol. Biol., 102, 11–21.
32. Lu, N.Z. and Cidlowski, J.A. (2005) Translational regulatory mechanisms
generate N-terminal glucocorticoid receptor isoforms with unique
transcriptional target genes. Mol. Cell., 18, 331–342.
3020 Human Molecular Genetics, 2008, Vol. 17, No. 19
 by guest on January 10, 2017
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
